EDUARDO MORENO ESCOBAR

Dr. EDUARDO MORENO ESCOBAR

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2025 in Circulation
Verified
Journal Article
Open access
SHSoledad García Hernandez
Soledad García Hernandez
LRLuis de la Higuera Romero
Luis de la Higuera Romero
AFAdrian Fernandez
Adrian Fernandez
MPMaria Luisa Peña Peña
Maria Luisa Peña Peña
NMNerea Mora-Ayestaran
Nerea Mora-Ayestaran
JOJuan Pablo Ochoa
Juan Pablo Ochoa
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disorder linked primarily to rare variants in sarcomeric genes, although recently certain nonsarcomeric genes have emerged as important contributors. Nonmendelian genetic variants with reproducible moderate-effect sizes and low penetrance, intermediate-effect variants (IEVs), can play a crucial role in modulating disease expression. Understanding the clinical impact of IEVs is crucial to unravel the complex genetic architecture of HCM. METHODS: We conducted an ancestry-based enrichment analysis of 14 validated HCM genes, including the 9 core sarcomeric and 5 nonsarcomeric genes (ALPK3 , CSRP3 , FHOD3 , FLNC , and TRIM63 ). Enrichment of intermediate frequency missense variants was evaluated in 10 981 patients with HCM, 4030 internal controls of European-ancestry, and 590 000 external controls from gnomAD non-Finnish Europeans. The population-attributable fraction was calculated to assess contribution of IEVs to HCM. Age-related disease penetrance, phenotypic severity (left ventricular maximum wall thickness), and major adverse cardiac events were analyzed in 11 991 HCM cases of the whole cohort according to 5 genetic groups: genotype negative, isolated IEV, monogenic, monogenic+IEV, and double monogenic. RESULTS: Fourteen IEVs in 8 genes were identified in 731 individuals (6.1% of the cohort), of whom 570 patients (4.8%) had IEVs in isolation: 198 (34.7%) in sarcomeric genes and 372 (65.3%) in nonsarcomeric genes. The contribution of IEVs to HCM genetics according to population-attributable fraction was estimated to be 4.9% (95% CI, 3.2–6.7). A significant gradient in penetrance, phenotypic severity, and major adverse cardiac events was observed across genetic groups. Compared with genotype-negative patients, IEV carriers displayed a younger median age at diagnosis (59 years of age [95% CI, 46–69] versus 61 years [95% CI, 49–70]; P =0.0073) and a higher mean left ventricular maximum wall thickness (18.1±3.7 versus 19.0±4.3; P =0.0043). IEVs also modified disease expression in individuals with monogenic variants, causing a more aggressive phenotype than in individuals from the monogenic-only group with HCM onset at younger age and a higher left ventricular maximum wall thickness (all P <0.0001), with major adverse cardiac event–free survival being significantly lower (93.3% versus 69.3% at 70 years of age; P <0.0001). CONCLUSIONS: IEVs are present in 6.1% of HCM cases and account for 4.8% of HCM genetic burden. IEVs also influence disease severity and outcomes, particularly when combined with monogenic disease-causing variants. Evaluation of IEVs should be considered when HCM genetic testing is performed.

2 June 2020 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
PEP. Escribano-Subias
P. Escribano-Subias
RLRaquel López
Raquel López
LALuis Almenar
Luis Almenar
MLMaría Lázaro
María Lázaro
IFIan Forn
Ian Forn
OIon behalf of the PRACMA investigators
on behalf of the PRACMA investigators
Macitentan is a dual endothelin receptor antagonist indicated for the long-term treatment of pulmonary arterial hypertension (PAH). We evaluated the change over time in REVEAL risk score in incident and prevalent patients receiving macitentan for the first time. Retrospective, observational study including adult patients with idiopathic/heritable PAH or PAH associated with connective tissue disorders or congenital heart disease treated with macitentan for ≥6-month follow-up in Spain. The REVEAL risk score and risk strata were computed at the start of macitentan and after ≥6-month in patients with ≥7 out of 12 valid REVEAL components. Overall, 81 patients (57 for the REVEAL score) were analysed, 77.8% women. The mean age was 57.2 years and 50.6% of patients had idiopathic/heritable PAH. Prevalent patients were 59.3 and 40.7% were incident. Main therapies for PAH included macitentan monotherapy (42.0%) and macitentan in combination with phosphodiesterase type 5 inhibitor (44.4%). With a median time of macitentan treatment of 10.5 months, the mean REVEAL score was 8.7 points at baseline and was 7.2 points after ≥6-month follow-up. The mean change (95% CI) in REVEAL risk score was − 1.4 (− 2.0, − 0.9) points (p < 0.0001), being − 1.8 (− 3.0, − 0.7) points (p = 0.0040) and − 1.2 (− 1.8, − 0.5) points (p = 0.0010), in incident and prevalent patients, respectively. The reduction was also significant by risk stratum (36.8% of patients in the high-very high risk strata at baseline versus 14.0% after ≥6-month, p < 0.05) and therapy group. The REVEAL components that significantly improved were WHO functional class (FC) (63.9% FC III at macitentan initiation and 23.6% after ≥6-month, p < 0.0001), 6-min walk test (mean change: 41.8 m, p < 0.01), brain natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP) (mean change of − 157.6 pg/mL and − 530.0 pg/mL, respectively, p < 0.05 both), and pulmonary vascular resistance (PVR) (mean change: − 3.4 WU, p < 0.01). In this study, treatment with macitentan improved the REVEAL risk strata and score in both incident and prevalent PAH patients, and in all patients regardless of the therapy strategy. Macitentan significantly improved some of REVEAL components including WHO FC, BNP/NT-proBNP, PVR, and 6-min walk test after at least 6-month follow-up.

1 June 2022 in Medicina Clinica
Verified
Journal Article
Closed access
RRRicardo Rubini-Costa
Ricardo Rubini-Costa
FBFrancisco José Bermúdez-Jiménez
Francisco José Bermúdez-Jiménez
RRRicardo Rivera-López
Ricardo Rivera-López
ESElena Sola-García
Elena Sola-García
HNHadi Nagib-Raya
Hadi Nagib-Raya
JJJuan Jiménez Jáimez
Juan Jiménez Jáimez

3 November 2026 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
CCCristina Cánovas-Galindo
Cristina Cánovas-Galindo
DSDiego Segura-Rodríguez
Diego Segura-Rodríguez
RLRaquel Ladrón-Abia
Raquel Ladrón-Abia
EEEDUARDO MORENO ESCOBAR
EDUARDO MORENO ESCOBAR

4 July 2026 in medRxiv
Verified
Preprint
Open access
JSJavier Sanchez-Martinez
Javier Sanchez-Martinez
Patricio Solis-UrraPatricio Solis-Urra
Patricio Solis-Urra
ATAngel Toval
Angel Toval
ACAndrea Coca-Pulido
Andrea Coca-Pulido
MPMaría Teresa Rodríguez Palacios
María Teresa Rodríguez Palacios
FOFrancisco B. Ortega
Francisco B. Ortega
Background: Coronary artery disease (CAD) increases the risk of cognitive impairment, dementia, and brain structural alterations. This heart-brain connection suggests that exercise-induced cardiovascular responses may influence brain regions vulnerable to Alzheimer's disease (AD), the most common cause of dementia. This study aimed to examine the effects of 12-weeks of either high-intensity interval training (HIIT) plus resistance training (RT) or HIIT alone on AD brain signatures in individuals with CAD, to explore moderating factors, and to assess associations between changes in AD brain signatures and cognition and physical fitness. Methods: This secondary analysis of a single-site, three-arm, single-blinded randomized controlled trial included 105 individuals with CAD (50-75 years; 21% female) randomly allocated to HIIT+RT, HIIT, or usual care (UC) groups. T1- and diffusion-weighted magnetic resonance imaging were acquired before and after the 12-week intervention. Primary outcomes were thickness/volume and gray matter mean diffusivity (GMMD) signatures, derived from seven cortical regions and the hippocampus. Moderators included age, sex, education, and baseline AD brain signatures. Results: For the thickness/volume signature, no between-group differences in changes were observed between HIIT+RT and UC (+0.13 standardized mean difference [SMD]; 95% CI, -0.07 to 0.33) or between HIIT and UC (-0.1 SMD; 95% CI, -0.3 to 0.1); however, a small but significant between-group difference in change was found between HIIT+RT and HIIT, in favor of HIIT+RT (+0.23 SMD; 95% CI, 0.03 to 0.42). For the GMMD signature, no significant between-group differences in changes were found between HIIT+RT and UC (+0.08 SMD; 95% CI, -0.18 to 0.34), HIIT and UC (+0.1 SMD; 95% CI, -0.16 to 0.36), or HIIT+RT and HIIT (-0.02 SMD; 95% CI, -0.28 to 0.23). No moderation effects were identified, and no associations were observed between changes in AD brain signatures and cognition or physical fitness. Conclusion: A 12-week HIIT+RT intervention was more effective than HIIT alone in increasing the thickness/volume signature in individuals with CAD, yet no differences were observed compared to UC and the interventions did not affect the GMMD signature. These findings suggest that the intra-session inclusion of RT with HIIT may enhance AD-related brain macrostructure in individuals with CAD more than just HIIT training.

8 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
GRGarcía-Orta Rocío
García-Orta Rocío
GMGonzález Molina Mercedes
González Molina Mercedes
UIUribe Morales Inés
Uribe Morales Inés
TLTorres Quintero Lucía
Torres Quintero Lucía
RJRodríguez Torres Diego J.
Rodríguez Torres Diego J.
EEEDUARDO MORENO ESCOBAR
EDUARDO MORENO ESCOBAR
Background: The objective of the study was to determine perioperative clinical and echocardiographic factors associated with pulmonary hypertension (PH) during long-term follow-up of patients with severe primary mitral regurgitation (MR) after mitral valve replacement surgery and its prognostic repercussions. Methods: Prospective cohort of consecutive patients undergoing mitral valve replacement between January 2005 and January 2015 and followed for ≥3 years. Main exclusion criteria were receipt of mitral repair surgery and the presence of mitral stenosis. The main outcome was a systolic pulmonary pressure (SPAP) by echocardiography >50 mmHg at least 12 months’ post-surgery. Results: 106 patients, 46% male, mean age of 61.7±11 yrs. and median follow-up of 8.8 [6- 16] yrs. SPAP was >50 mmHg in 33% of patients. Predictors identified by multivariate analysis were diabetes (OR 8.3, 95%CI 1.1-73.9), persistent atrial fibrillation (OR 4.2, 95%CI 1.1-20.6), non-rheumatic MR (OR 7.3, 95%CI 1.1-45.5), prosthesis gradient, (OR 2.8, 95%CI 1.3-5.7), patient-prosthesis mismatch (OR 16.9, 95%CI 1.2-234), and preoperative SPAP ≥50 mmHg (OR 19.3, 95%CI 3.4-107). Patients with PH had higher hospitalization (78.8 % vs. 37%, p<0.001) and mortality (72,4% vs. 19,7%, p<0.001) rates. The 10-year survival rate was 83% in patients without PH versus 30% in those with PH (p<0.001). Conclusions: Persistent PH is a frequent and serious long-term complication of valve replacement for severe mitral regurgitation. It is associated with a poor prognosis and is related to preoperative pulmonary pressure. Surgery could be considered in candidates for mitral valve replacement with moderate PH, especially in the presence of atrial fibrillation. Clinical perspective: What is already known on this topic: Pulmonary hypertension is not reversed in an important subset of patients with severe mitral regurgitation after mitral valve replacement surgery and it is associated with a poor prognosis. No prospective study has been published on preoperative factors associated with this condition. The prevalence and prognosis of postoperative PH has not been precisely described. What this study adds: Persistent PH after valve replacement for severe mitral regurgitation is common and its prognosis is ominous. Preoperative SPAP ≥50 mmHg and persistent atrial fibrillation are the main predictive factors. The results of this study might affect clinical practice suggesting considering surgery in this population (not only in mitral valve repair) when SPAP ≥50 mmHg, especially if persistent atrial fibrillation. Graphical